

## Datasheet: MCA1557F

|                      |                             |
|----------------------|-----------------------------|
| <b>Description:</b>  | MOUSE ANTI HUMAN CD105:FITC |
| <b>Specificity:</b>  | CD105                       |
| <b>Other names:</b>  | ENDOGLIN                    |
| <b>Format:</b>       | FITC                        |
| <b>Product Type:</b> | Monoclonal Antibody         |
| <b>Clone:</b>        | SN6                         |
| <b>Isotype:</b>      | IgG1                        |
| <b>Quantity:</b>     | 0.1 mg                      |

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

|                | Yes | No | Not Determined | Suggested Dilution |
|----------------|-----|----|----------------|--------------------|
| Flow Cytometry | ■   |    |                | Neat               |

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

| <b>Target Species</b>                 | Human  |                   |                     |                   |      |     |     |  |  |
|---------------------------------------|--|-------------------|---------------------|-------------------|------|-----|-----|--|--|
| <b>Species Cross Reactivity</b>       | Reacts with: Horse, Cynomolgus monkey, Rhesus Monkey<br>Based on sequence similarity, is expected to react with: Primate<br><b>N.B.</b> Antibody reactivity and working conditions may vary between species. |                   |                     |                   |      |     |     |  |  |
| <b>Product Form</b>                   | Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid   |                   |                     |                   |      |     |     |  |  |
| <b>Max Ex/Em</b>                      | <table border="1"> <thead> <tr> <th>Fluorophore</th> <th>Excitation Max (nm)</th> <th>Emission Max (nm)</th> </tr> </thead> <tbody> <tr> <td>FITC</td> <td>490</td> <td>525</td> </tr> </tbody> </table>     | Fluorophore       | Excitation Max (nm) | Emission Max (nm) | FITC | 490 | 525 |  |  |
| Fluorophore                           | Excitation Max (nm)  | Emission Max (nm) |                     |                   |      |     |     |  |  |
| FITC                                  | 490  | 525               |                     |                   |      |     |     |  |  |
| <b>Preparation</b>                    | Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant  |                   |                     |                   |      |     |     |  |  |
| <b>Buffer Solution</b>                | Phosphate buffered saline  |                   |                     |                   |      |     |     |  |  |
| <b>Preservative</b>                   | 0.09% Sodium Azide   |                   |                     |                   |      |     |     |  |  |
| <b>Stabilisers</b>                    | 1% Bovine Serum Albumin  |                   |                     |                   |      |     |     |  |  |
| <b>Approx. Protein Concentrations</b> | IgG concentration 0.1 mg/ml  |                   |                     |                   |      |     |     |  |  |
| <b>Immunogen</b>                      | Partially purified cell membrane antigens from fresh leukemia cells  |                   |                     |                   |      |     |     |  |  |

**External Database  
Links**

**UniProt:**

[P17813](#)   [Related reagents](#)

**Entrez Gene:**

[2022](#)   ENG   [Related reagents](#)

---

**Synonyms**

END

---

**Fusion Partners**

Spleen cells from immunised BALB/c mice were fused with cells of the mouse P3/NS1/1-Ag4-1 myeloma cell line

---

**Specificity**

**Mouse anti Human CD105 antibody, clone SN6** recognizes the human endoglin, also known as CD105. CD105 is a glycoprotein homodimer of ~95 kDa subunits expressed by endothelial cells, activated monocytes and some leukemia cells.

---

**Flow Cytometry**

Use 10ul of the suggested working dilution to label 10<sup>6</sup> cells in 100ul.

---

**References**

1. Haruta, Y. & Seon, B.K. (1986) Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. [Proc Natl Acad Sci USA 83 \(20\): 7898-902.](#)
2. Jin, H.J. *et al.* (2010) GD2 expression is closely associated with neuronal differentiation of human umbilical cord blood-derived mesenchymal stem cells. [Cell Mol Life Sci. 67 \(11\): 1845-58.](#)
3. Nagano, M. *et al.* (2007) Identification of functional endothelial progenitor cells suitable for the treatment of ischemic tissue using human umbilical cord blood. [Blood 110 \(1\): 151-60.](#)
4. Braun, J. *et al.* (2010) Evaluation of the osteogenic and chondrogenic differentiation capacities of equine adipose tissue-derived mesenchymal stem cells. [Am J Vet Res. 71 \(10\): 1228-36.](#)
5. Diaz-Romero, J. *et al.* (2008) Immunophenotypic changes of human articular chondrocytes during monolayer culture reflect bona fide dedifferentiation rather than amplification of progenitor cells. [J Cell Physiol. 214: 75-83.](#)
6. Agha-Hosseini, F. *et al.* (2010) *In vitro* isolation of stem cells derived from human dental pulp. [Clin Transplant. 24: E23-8.](#)
7. Arufe, M.C. *et al.* (2010) Chondrogenic potential of subpopulations of cells expressing mesenchymal stem cell markers derived from human synovial membranes. [J Cell Biochem. 111: 834-45.](#)
8. Balmayor, E.R. *et al.* (2011) Synthesis and functionalization of superparamagnetic poly-ε-caprolactone microparticles for the selective isolation of subpopulations of human adipose-derived stem cells. [J R Soc Interface 8: 896-908.](#)
9. Benetti, A. *et al.* (2008) Transforming growth factor-beta1 and CD105 promote the migration of hepatocellular carcinoma-derived endothelium. [Cancer Res. 68: 8626-34.](#)
10. Ciccocioppo, R. *et al.* (2011) Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. [Gut 60: 788-98.](#)
11. Cox, G. *et al.* (2011) The use of the reamer-irrigator-aspirator to harvest mesenchymal stem cells. [J Bone Joint Surg Br. 93: 517-24.](#)
12. Ferro, F. *et al.* (2010) Biochemical and biophysical analyses of tissue-engineered bone obtained from three-dimensional culture of a subset of bone marrow mesenchymal stem cells. [Tissue Eng Part A 16: 3657-67.](#)
13. Lozanoska-Ochser, B. *et al.* (2008) Expression of CD86 on human islet endothelial cells facilitates T cell adhesion and migration. [J Immunol. 181: 6109-16.](#)
14. Sallustio, F. *et al.* (2010) TLR2 plays a role in the activation of human resident renal stem/progenitor cells. [FASEB J. 24: 514-25.](#)
15. Tso, C. *et al.* (2012) Phenotypic and functional changes in blood monocytes following adherence to endothelium. [PLoS One 7: e37091.](#)
16. Hu, N. *et al.* (2013) Long-term outcome of the repair of 50 mm long median nerve defects in

rhesus monkeys with marrow mesenchymal stem cells-containing, chitosan-based tissue engineered nerve grafts. [Biomaterials 34: 100-11.](#)

17. Cho, H.J. *et al.* (2013) Generation of human secondary cardiospheres as a potent cell processing strategy for cell-based cardiac repair. [Biomaterials 34: 651-61.](#)

18. Kang, S.D. *et al.* (2013) Isolation of Functional Human Endothelial Cells from Small Volumes of Umbilical Cord Blood. [Ann Biomed Eng. 41: 2181-92.](#)

19. Mehrkens, A. *et al.* (2013) Non-adherent mesenchymal progenitors from adipose tissue stromal vascular fraction. [Tissue Eng Part A 20: 1081-8.](#)

20. De Schauwer, C. *et al.* (2012) In search for cross-reactivity to immunophenotype equine mesenchymal stromal cells by multicolor flow cytometry. [Cytometry A 81: 312-23.](#)

21. Zhang, J. *et al.* (2016) Bone mesenchymal stem cells differentiate into myofibroblasts in the tumor microenvironment. [Oncology Letters. May 30 \[Epub ahead of print\]](#)

22. Morsing, M. *et al.* (2016) Evidence of two distinct functionally specialized fibroblast lineages in breast stroma. [Breast Cancer Res. 18 \(1\): 108.](#)

23. Williamson, K.A. *et al.* (2015) Restricted differentiation potential of progenitor cell populations obtained from the equine superficial digital flexor tendon (SDFT). [J Orthop Res. 33 \(6\): 849-58.](#)

24. Lützkendorf, J. *et al.* (2017) Resistance for Genotoxic Damage in Mesenchymal Stromal Cells Is Increased by Hypoxia but Not Generally Dependent on p53-Regulated Cell Cycle Arrest. [PLoS One. 12 \(1\): e0169921.](#)

25. Lee, H.J. *et al.* (2017) ICOSL expression in human bone marrow-derived mesenchymal stem cells promotes induction of regulatory T cells. [Sci Rep. 7: 44486.](#)

26. Yi, T. *et al.* (2015) Manufacture of Clinical-Grade Human Clonal Mesenchymal Stem Cell Products from Single Colony Forming Unit-Derived Colonies Based on the Subfractionation Culturing Method. [Tissue Eng Part C Methods. 21 \(12\): 1251-62.](#)

27. Boccardo, S. *et al.* (2016) Engineered mesenchymal cell-based patches as controlled VEGF delivery systems to induce extrinsic angiogenesis. [Acta Biomater. 42: 127-35.](#)

28. Mumaw, J.L. *et al.* (2015) Feline mesenchymal stem cells and supernatant inhibit reactive oxygen species production in cultured feline neutrophils. [Res Vet Sci. 103: 60-9.](#)

29. Bertolo, A. *et al.* (2017) Oxidative status predicts quality in human mesenchymal stem cells. [Stem Cell Res Ther. 8 \(1\): 3.](#)

30. GarikipatiV, N.S. *et al.* (2018) Isolation and characterization of mesenchymal stem cells from human fetus heart. [PLoS One. 13 \(2\): e0192244.](#)

31. Olimpio, R.M.C. *et al.* (2018) Cell viability assessed in a reproducible model of human osteoblasts derived from human adipose-derived stem cells. [PLoS One. 13 \(4\): e0194847.](#)

---

**Further Reading**

1. Burk, J. *et al.* (2013) Equine cellular therapy--from stall to bench to bedside? [Cytometry A 83 \(1\): 103-13.](#)

2. Carrade, D.D. *et al.* (2012) Comparative Analysis of the Immunomodulatory Properties of Equine Adult-Derived Mesenchymal Stem Cells. [Cell Med. 4: 1-11.](#)

---

**Storage**

Store at +4°C or at -20°C if preferred.

This product should be stored undiluted.

Storage in frost free freezers is not recommended. This product is photosensitive and should be protected from light.

Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.

---

**Shelf Life**

18 months from date of despatch.

---

**Health And Safety**

Material Safety Datasheet documentation #10041 available at:

**Information** 10041: <https://www.bio-rad-antibodies.com/uploads/MSDS/10041.pdf>

---

**Regulatory** For research purposes only

---

## Related Products

### Recommended Negative Controls

[MOUSE IgG1 NEGATIVE CONTROL:FITC \(MCA928F\)](#)

### Recommended Useful Reagents

[HUMAN SEROBLOCK \(BUF070A\)](#)

[HUMAN SEROBLOCK \(BUF070B\)](#)

**North & South** Tel: +1 800 265 7376

**America** Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe**

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

'M301239:170109'

**Printed on 05 May 2018**

---

© 2018 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)